Literature DB >> 10653451

Hepatitis C virus genotypes and quasispecies.

G L Davis1.   

Abstract

Genetic heterogeneity is a hallmark of the hepatitis C virus, as a result largely of the infidelity of viral RNA-dependent RNA polymerase. Random nucleotide substitutions are introduced at a very high rate. The existence of genotypes was confirmed by statistical and mathematical techniques, and the relation of the genotypes to each other has been determined. There are six major genotypes, each with multiple subtypes. Isolates of the same genotype have an average sequence homology of 95%, but different genotypes have sequence similarity of approximately 65% on average. The nucleotide sequence in portions of the hepatitis C viral genome, including the 5' noncoding region, part of the core gene, and other nonstructural proteins, is highly conserved. Genotype analysis typically utilizes these highly conserved regions. There are many techniques for determining viral genotype, and in general, concordance between techniques is good. Methods most commonly used for assigning hepatitis C virus (HCV) genotypes in clinical practice include restriction fragment length polymorphism analysis and the reverse hybridization line probe assay (LiPA; Innogenetics, Ghent, Belgium). The worldwide distribution of HCV genotypes has been determined; some genotypes are highly characteristic of certain areas. The most common subtypes, 1 and 2, are less genetically diverse than the others and are more widely distributed. The impact of genotype on disease course is controversial, but recent data suggest that there is a genotype-dependent differential response to therapy. Quasispecies refers to evolution of a highly related but genetically heterogeneous population of HCV isolates. The pathobiological and clinical implications of HCV quasispecies are poorly understood.

Entities:  

Mesh:

Year:  1999        PMID: 10653451     DOI: 10.1016/s0002-9343(99)00376-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  24 in total

Review 1.  Laboratory assays for diagnosis and management of hepatitis C virus infection.

Authors:  Sandra S Richter
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.

Authors:  Anita Y M Howe; Huiming Cheng; Ian Thompson; Srinivas K Chunduru; Steve Herrmann; John O'Connell; Atul Agarwal; Rajiv Chopra; Alfred M Del Vecchio
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Gary L. Davis, MD: a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Gary L Davis
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

4.  Improving Metabolic Stability with Deuterium: The Discovery of BMT-052, a Pan-genotypic HCV NS5B Polymerase Inhibitor.

Authors:  Kyle Parcella; Kyle Eastman; Kap-Sun Yeung; Katharine A Grant-Young; Juliang Zhu; Tao Wang; Zhongxing Zhang; Zhiwei Yin; Dawn Parker; Kathy Mosure; Hua Fang; Ying-Kai Wang; Julie Lemm; Xiaoliang Zhuo; Umesh Hanumegowda; Mengping Liu; Karen Rigat; Maria Donoso; Maria Tuttle; Tatyana Zvyaga; Zuzana Haarhoff; Nicholas A Meanwell; Matthew G Soars; Susan B Roberts; John F Kadow
Journal:  ACS Med Chem Lett       Date:  2017-06-29       Impact factor: 4.345

5.  Virus genotype 1b and long-term response to interferon alpha monotherapy in children with chronic hepatitis C.

Authors:  Iwona Mozer-Lisewska; Wojciech Słuzewski; Khaled Ali Youseif; Magdalena Figlerowicz; Arleta Kowala-Piaskowska
Journal:  Eur J Pediatr       Date:  2003-08-22       Impact factor: 3.183

6.  Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs.

Authors:  Saba Khaliq; Shah Jahan; Bushra Ijaz; Waqar Ahmad; Sultan Asad; Asim Pervaiz; Baila Samreen; Mahwish Khan; Sajida Hassan
Journal:  Virol J       Date:  2010-11-13       Impact factor: 4.099

Review 7.  Production and pathogenicity of hepatitis C virus core gene products.

Authors:  Hui-Chun Li; Hsin-Chieh Ma; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 8.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

9.  A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses.

Authors:  Li-Xin Zhu; Jing Liu; Ye Ye; You-Hua Xie; Yu-Ying Kong; Guang-Di Li; Yuan Wang
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

10.  Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Authors:  Ekaterina Alekseeva; Irina Sominskaya; Dace Skrastina; Irina Egorova; Elizaveta Starodubova; Eriks Kushners; Marija Mihailova; Natalia Petrakova; Ruta Bruvere; Tatyana Kozlovskaya; Maria Isaguliants; Paul Pumpens
Journal:  Genet Vaccines Ther       Date:  2009-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.